Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:BGNE

BeiGene (BGNE) Stock Price, News & Analysis

BeiGene logo

About BeiGene Stock (NASDAQ:BGNE)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$174.72
$217.22
52-Week Range
N/A
Volume
331,608 shs
Average Volume
335,598 shs
Market Capitalization
$18.03 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$253.92
Consensus Rating
Moderate Buy

Company Overview

Receive BGNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BeiGene and its competitors with MarketBeat's FREE daily newsletter.

BGNE Stock News Headlines

The $100 Trillion AI Story No One Is Telling You
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
See More Headlines

BGNE Stock Analysis - Frequently Asked Questions

BeiGene, Ltd. (NASDAQ:BGNE) posted its earnings results on Tuesday, November, 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.11) by $0.04. BeiGene's quarterly revenue was up 28.2% compared to the same quarter last year.

BeiGene (BGNE) raised $126 million in an initial public offering on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that BeiGene investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD), ServiceNow (NOW) and Saia (SAIA).

Company Calendar

Last Earnings
11/12/2024
Today
7/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BGNE
Fax
N/A
Employees
9,000
Year Founded
2010

Price Target and Rating

Average Stock Price Target
$253.92
High Stock Price Target
$300.00
Low Stock Price Target
$152.50
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$881.71 million
Pretax Margin
-24.07%

Debt

Sales & Book Value

Annual Sales
$3.32 billion
Price / Cash Flow
N/A
Book Value
$37.10 per share
Price / Book
N/A

Miscellaneous

Free Float
90,195,000
Market Cap
$18.03 billion
Optionable
Optionable
Beta
0.57

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:BGNE) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners